The second HDAC inhibitor approved for the treatment of CTCL was based on two large phase II studies: a multi-institutional study based at the NCI in the US (71 patients), and an international study (96 patients) [27,28]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.